Anti Aging
Hair Growth
Muscle Growth
Peptide Blends
Peptide Supplies
Peptides
Skin
Testosterone
Weight Loss-
Oxytocin 10mg $50.00
Oxytocin, also known as the love hormone, helps us bond with our loved ones and is often released through touch, exercise, and music.
What is Oxytocin?
This natural hormone manages crucial aspects of male and female reproductive systems, including lactation, labor, delivery, and certain aspects of human behavior. The hypothalamus produces oxytocin, but the posterior pituitary gland releases and stores this hormone into the bloodstream.
Hormones are chemicals that manage various functions in the human body by carrying messages through blood to tissues, muscles, and organs. These signals instruct your body what to do and when to do it.
The hypothalamus is part of the brain that controls functions such as heart rate, digestion, body temperature, and blood pressure. On the other hand, the pituitary gland is a small, pea-sized endocrine gland placed at the base of the brain, below the hypothalamus.
Synthetic Forms of Oxytocin
A synthetic form of oxytocin is used in hospital settings, particularly when doctors need to induce labor in childbirth if it hasn’t begun naturally or to help with contractions. Healthcare providers may also use this hormone to speed up the delivery of the placenta, which is the third stage of labor, and minimize the risk of heavy bleeding.
Function of Oxytocin
As previously mentioned, the two main functions of oxytocin are to encourage uterine contractions in childbirth and labor and to boost contractions of breast tissue to help with lactation after childbirth.
However, apart from these, oxytocin has other important roles, such as:
- Placenta-infant bonding
- Romantic attachment
- Trust
- Recognition
- Sexual arousal
The effects of oxytocin on the human brain are complex, and scientists are currently researching the role of oxytocin in various conditions.
- PTSD
- Depression
- Autism spectrum disorder
- Anxiety
- Anorexia
- Addiction
Florea T, Palimariciuc M, Cristofor AC, Dobrin I, Chiriță R, Bîrsan M, Dobrin RP, Pădurariu M. Oxytocin: Narrative Expert Review of Current Perspectives on the Relationship with Other Neurotransmitters and the Impact on the Main Psychiatric Disorders. Medicina (Kaunas). 2022 Jul 11;58(7):923. doi: 10.3390/medicina58070923. PMID: 35888641; PMCID: PMC9318841.
Kendrick KM, Guastella AJ, Becker B. Overview of Human Oxytocin Research. Curr Top Behav Neurosci. 2018;35:321-348. doi: 10.1007/7854_2017_19. PMID: 28864976.
https://www.sciencedirect.com/science/article/pii/S0306453013002369
-
PT-141 $55.00
Also called Bremelanotide, PT-141 is a synthetic melanocortin receptor agonist that promotes dopamine release. Since it has such a high affinity for MC4R (Melanocortin 4 Receptor), in the presynaptic neurons of the hypothalamus, it has been approved as a treatment for HSDD (hypoactive sexual desire disorder) in premenopausal women. Under the brand name Vyleesi, Bremelanotide is the first and only FDA-approved way of HSDD treatment.
Sexual Dysfunctions
As we already said, PT-141 is an effective treatment for HSDD in premenopausal women but it’s important to note it should not be used as a treatment in women who already went through menopause or as a way of boosting sexual performance in men. These have not yet been fully tested.
We’ve seen the effectiveness of PT-141 (Bremelanotide) demonstrated in numerous studies. One such study followed female test subjects over the course of 52 weeks where the treated group received a 1.75mg dose right before anticipated sexual intercourse. All participants showed higher scores on general arousal, desire and orgasm, as compared to the placebo group. Also, no major side effects were linked to PT-141 application – the “most severe” ones were nausea, flushing and headache, which only occurred in around 10% of the participants.
Interestingly enough, scientists are still unsure about the Bremelanotide’s exact mechanism of action and how it leads to increased sexual desire in female patients. All we know is that it’s a potent alpha melanocyte-stimulating hormone, binding predominantly to the receptors MC4R and MC1R, and, to a certain extent, to MC1R-MC5R.
PT-141 And Erectile Dysfunction
At the beginning of the article we said that PT-141 (bremelanotide) should not be used to increase sexual desire in men… but this is not entirely true as there is some emerging evidence that this peptide does affect male sexual performance.
Currently, there are a number of effective ED treatment options available. One of the most fail-proof and common ones, incidentally the most invasive one, is an intracavernosal injection – where an injection is applied directly to corpus cavernosum (spongy tissue that runs through the shaft of the penis).
Naturally, researchers are on the lookout for a new, less invasive treatment option and are testing PT-141 as such. Though research is still in its early stages, results showed significant increases in both duration and the erection quality in both “regular” men, as well as those known to be taking viagra.
We still need more research to confirm all these findings and determine the safety and efficacy of using PT-14 as a reliable ED treatment option, but clinical studies suggest we are heading in this direction.
https://www.sciencedirect.com/topics/medicine-and-dentistry/bremelanotide
-
Retatrutide 5mg/10mg $150.00 – $270.00
Retatrutide is one of the latest incretin mimetic drugs being tested for their weight reduction properties. Researchers use incretin mimetic agents as they work to mimic incretin hormones (gut peptides that get secreted after we eat) to allow for a better insulin secretion and hyperglycaemic control.
Even though there are numerous weight reduction agents being prescribed and used, FDA-recognized “treatment” for nonsyndromic obesity are:
- Orlistat
- Phentermine-topiramate
- Naltrexone‐bupropion
- Liraglutide and
- Semaglutide
With the exception of glucagon-like peptide 1 receptor agonists (such as semaglutide), most weight reduction agents come with a specific set of side effects such as nausea, gastrointestinal distress, abdominal pain, vomiting, diarrhea, or a general weight decrease that does not cross the 15% mark. Some of these medications even come with a warning against using them if a patient is suffering from a kidney, heart, thyroid or any related problems.
This is why scientists are turning more and more to retatrutide, because this incretin mimetic decreases appetite, promotes the feeling of fullness and slows down the process of gastric emptying, but does all that while presenting with minimal side effects and increased weight loss effectiveness, compared to liraglutide or semaglutide.
Retatrutide Mechanism of Action
Retatrutide exerts a powerful glucagon-receptor agonistic effect. When we compare it to human glucagon and glucagon-like peptide 1 (GLP-1), it exhibits:
- Reduced potency on the GCGR (human glucagon receptor) and GLP-1R (glucagon-like peptide-1 receptor)
- Enhanced potency at the human GIPR (gastric inhibitory polypeptide receptor)
When talking about in vitro experiments, retatrutide demonstrated similar efficacy in evoking glucose production within hepatocytes and inducing lipolysis. Also, retatrutide showed a favorable half-life of 6 days, enabling it a weekly dosage regimen (should the drug get FDA approved).
Another double-blind study conducted in the US on obese patients showed promising results. 338 adults in total were involved, split into 6 cohorts (depending on the weekly dosage), up against a placebo group. Retatritude group experienced the following results:
- 1mg group – after 24 weeks this group experienced weight loss of 7.2%, and after 48 weeks a total loss of 8.7%
- 4mg group (commencing with 2mg) – after 24 weeks this group experienced a weight loss of 11.8%, and after 48 weeks a total loss of 16.3%
- 4mg group (commencing with 4mg) – after 24 weeks this group experienced a weight loss of 13.9%, and after 48 weeks a total loss of 17.8%
- 8mg group (commencing with 2mg) – after 24 weeks this group experienced a weight loss of 16.7%, and after 48 weeks a total loss of 21.7%
- 8mg group (commencing with 4mg) – after 24 weeks this group experienced a weight loss of 17.9%, and after 48 weeks a total loss of 23.9%
- 12mg group (commencing with 2mg) – after 24 weeks this group experienced a weight loss of 17.5%, and after 48 weeks a total loss of 24.2%
In contrast, the placebo group only experienced a 1.6% weight loss after 24 weeks and 2.1% after 48. Findings also showed that adverse effects related to retratitude treatment (such as nausea, vomiting, diarrhea and constipation), were mild and depended on the dosage.
In conclusion, this peptide showed promising results in addressing obesity in both in vitro and human test subject studies. However, test samples were relatively small, and we still need more research and clinical trials to show the effectiveness of retratutide as an effective, long-term way of managing weight.
Reference:
Naeem M, Imran L, Banatwala UESS. Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence. Health Sci Rep. 2024 Feb 5;7(2):e1864. doi: 10.1002/hsr2.1864. PMID: 38323122; PMCID: PMC10844714.
-
Semaglutide (GLP-1) 5mg/10mg $105.00 – $190.00
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.It is one of the two primary hormones that may enhance incretin activity in rodent models, along with GIP.
GLP-1 is one of the major incretin (gut peptide secreted after nutrient intake) hormones in humans. It plays a pivotal role in many different mechanisms within the body:
- Insulin secretion
- Inhibits glucagon release (glucagon is secreted as a response in blood sugar drop)
- Suppresses hepatic gluconeogenesis (glycogen is the primary carbohydrate stored in the liver)
- Delays gastric emptying
- Reduces appetite and energy intake
When talking about obese diabetic 2 type patients, GLP-1 assumes a special status in their treatment as it lowers HbA1c levels along with body weight, but without the risk of hypoglycemia.
However, the biggest problem with GLP-1 is its short half-live (of only 1 to 2 minutes) and this is why researchers turner to various other GLP-1 receptor agonists, such as liraglutide, dulaglutide and, of course, semaglutide. Another thing researchers hope to achieve by turning to GLP-1 agonists, such as semaglutide, is to develop an effective diabetes management drug which needs less frequent dosing.
Murine models suggested that semaglutide’s GLP-1 receptor activation affects insulin secretion, blood sugar homeostasis and beta cell protection. Further, in vitro studies showed its potential to also affect glucagon secretion. This insulin glucagon mechanics is what’s used to balance our pancreatic function and regulate metabolism.
References:
- Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 2022 Jun;23(3):521-539. doi: 10.1007/s11154-021-09699-1. Epub 2022 Jan 7. PMID: 34993760; PMCID: PMC8736331.
- Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012 Dec;8(12):728-42. doi: 10.1038/nrendo.2012.140. Epub 2012 Sep 4. PMID: 22945360.
500 in stock
-
Semax 50mg $60.00 – $110.00
Semax is an interesting nootropic that can capture the attention of researchers, health professionals, and enthusiasts alike. It was originally developed in Russia back in the 1980s and 1990s. Nowadays, Semax is believed to enhance a range of cognitive and neuroprotective properties.
Many know this peptide by its trade name, such as Semaxum, and it has been extensively researched by institutions such as the Institute of Molecular Genetics of the Russian Academy of Science.
What is Semax?
Semax is a peptide best known for its neurogenic, neuroprotective, and nootropic properties. It was developed based on the molecular structure of ACTH or adrenocorticotropic hormone. Preliminary studies in small-scale human trials, animals, and cells indicate potential benefits of Semax use.
In the U.S. and multiple countries around the world, this component is the basis for a number of medicines that are used in clinical practices for the treatment of optic nerve atrophy, dys-circulatory encephalopathy, and ischemic brain stroke.
Potential benefits
Some of the benefits Semax may include:
- Increased short-term memory and attention
- Better non-proliferative diabetic neuropathy
- Can assist during recovery from hypoxia/stroke
- Can help with glaucoma optic neuropathy
- May act as an analgesic
- It may help in treating ADHD
- It may help protect the brain from various types of damage and stress
How Does Semax Work?
Semax increases BDNF or brain-derived neurotrophic factor. BDNF is one of the most active neurotrophins, which help control and stimulate neurogenesis, creating new neurons in the brain. This component helps support neuroplasticity, allowing nerve cells in the brain to adapt to new situations and recover from injury.
Additionally, BDNF encourages the survival of existing neurons and supports the growth, creation, and regeneration of new synapses and neurons.
This nootropic also helps minimize the breakdown of enkephalins. Enkephalins are mostly involved in reducing inflammation, decreasing pain, boosting immune cell activity, and preventing cancer cell growth.
They also play a role in pain, emotional behavior, learning, and memory. Balanced enkephalins are necessary to maintain normal brain function. Therefore, researchers are led to believe that Semax may potentially relieve pain. However, more research is needed to confirm the preliminary findings.
References:
Medvedeva EV, Dmitrieva VG, Povarova OV, Limborska SA, Skvortsova VI, Myasoedov NF, Dergunova LV. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014 Mar 24;15:228. doi: 10.1186/1471-2164-15-228. PMID: 24661604; PMCID: PMC3987924.
https://www.sciencedirect.com/science/article/abs/pii/S0306987706005391
Gusev, E. & Martinov, Michail & Kostenko, E. & Petrova, Lyudmila & Bobyreva, S.. (2018). The efficacy of semax in the tretament of patients at different stages of ischemic stroke. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 118. 61. 10.17116/jnevro20181183261-68.
-
Sermorelin 10mg $90.00
Growth hormone replacement therapy has long been accepted as one of the most effective ways of treating GH deficiency and related conditions. This therapy uses recombinant human growth hormone (rhGH) and, despite its longstanding usage record, it has been surrounded by controversy. Even though, in the short term, this therapy is very effective, when it comes to long term effects, issues start to arise:
- Long term improper dosage can lead to some severe side effects
- This therapy may affect normal physiology after prolonged application
- Some federal regulations might interfere with the therapy
- There’s even some concerns that this therapy may awaken latent cancers and cause metabolic disorders
There is one more major problem with dosage because the body can’t properly modulate tissue exposure to rhGH. Meaning, the practitioner uses their “best guess” to access the appropriate dosage.
This is why researchers are looking for alternative ways to stimulate GH production by targeting GH secretagogues and promoting pituitary gland health. One such molecule is sermorelin, a GHRH analog that impacts the hypothalamic-pituitary-pituitary-somatotropic axis.
It’s used for both treatment and diagnosis of GH deficiency as research studies showed sermorelin promoted change in GH levels similar to those observed with endogenous GHRH. It also stimulates FSH (follicle-stimulating hormone) and LH (luteinizing hormone), which implies a potential role in the treatment of hypogonadism.
Though we need larger, longitudinal studies, sermorelin proved as a promising GH and IGF-1 stimulator and diagnostic agent.
Reference:
Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-8. doi: 10.2147/ciia.2006.1.4.307. PMID: 18046908; PMCID: PMC2699646.
Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159. doi: 10.21037/tau.2019.11.30. PMID: 32257855; PMCID: PMC7108996.
-
Sermorelin and Ipamorelin Peptide Blend $100.00
In medical circles, Sermorelin and Ipamorelin are often mentioned as a fountain of youth. While no single ingredient has the ability to reverse the aging process and stop our cells from deteriorating, this blend has shown promising results in a laboratory setting.
Both ingredients are human growth hormone-releasing peptides that stimulate the pituitary gland. Based on the studies conducted on animals, they are believed to preserve youthful anatomy and psychology.
What is Sermorelin?
Sermorelin is a synthetically made version of GHRH, or growth hormone-releasing hormone, which is responsible for promoting the natural release of growth hormone. It works by binding GHRH to the anterior part of the pituitary gland, stimulating the natural production of GH.
When doing research on rats and primates, scientists came up with the following benefits:
Sermorelin was able to:
- Increase muscles
- Increase lean body mass
- Decrease body fat
- Boost recovery from training sessions and injuries
- Enhance joint health and flexibility
- Improve overall wellness and health
What is Ipamorelin?
As the previous compound, Ipamorelin stimulates the release of growth hormone while reducing the release of somatostatin. Based on laboratory research, Ipamorelin has demonstrated the following benefits in the domain of anti-aging:
- Increased bone density
- Loss of body fat in obese adults
- Increased muscle mass
- Better immune system
- Improved cellular protein synthesis
Sermorelin and Ipamorelin Blend
These two peptides are often combined because they are believed to slow down aging processes, increase muscle mass, minimize inflammation, decrease fat mass, and health the gut. Research in pigs indicates that Sermorelin minimizes cell death of cardiomyocytes, boosts healing after cardiac injury, improves the collateral blood vessels, and reduces inflammation.
In addition to this, the administration of ghrelin analogues and ghrelin has been shown to lower abnormal heartbeats.
It has also been found that Sermorelin and Ipamorelin can benefit the central nervous system and boost sleep quality in animal models.
References:
Bagno LL, Kanashiro-Takeuchi RM, Suncion VY, Golpanian S, Karantalis V, Wolf A, Wang B, Premer C, Balkan W, Rodriguez J, Valdes D, Rosado M, Block NL, Goldstein P, Morales A, Cai RZ, Sha W, Schally AV, Hare JM. Growth hormone-releasing hormone agonists reduce myocardial infarct scar in swine with subacute ischemic cardiomyopathy. J Am Heart Assoc. 2015 Mar 31;4(4):e001464. doi: 10.1161/JAHA.114.001464. PMID: 25827134; PMCID: PMC4579962.
Kanashiro-Takeuchi RM, Szalontay L, Schally AV, Takeuchi LM, Popovics P, Jaszberenyi M, Vidaurre I, Zarandi M, Cai RZ, Block NL, Hare JM, Rick FG. New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget. 2015;6(12):9728-39. doi: 10.18632/oncotarget.3303. PMID: 25797248; PMCID: PMC4496393.
Tokudome T, Otani K, Miyazato M, Kangawa K. Ghrelin and the heart. Peptides. 2019 Jan;111:42-46. doi: 10.1016/j.peptides.2018.05.006. Epub 2018 May 20. PMID: 29791869.
Shepherd BS, Johnson JK, Silverstein JT, Parhar IS, Vijayan MM, McGuire A, Weber GM. Endocrine and orexigenic actions of growth hormone secretagogues in rainbow trout (Oncorhynchus mykiss). Comp Biochem Physiol A Mol Integr Physiol. 2007 Mar;146(3):390-9. doi: 10.1016/j.cbpa.2006.11.004. Epub 2006 Nov 24. PMID: 17240179.
-
TB-500 10mg $80.00 – $140.00
TB-500 is a 43 amino acid long synthetic peptide, analogue of thymosin beta-4. Thymosin beta-4 is a widely distributed peptide, and present in virtually all mammalian cells, which plays a pivotal role in many different processes in the body – it increases angiogenesis (formation of new blood vessels), proliferation, inhibits apoptosis (cell death) and inflammation.
Numerous animal clinical trials also showed that thymosin beta-4 can be used to indicate myocardial, liver and renal problems.
Angiogenesis:
Thymosin beta-4 promotes angiogenesis, triggers cell proliferation and migration, as well as the formation of capillary-like structures in cells. It also triggers blood perfusion (local fluid flow) by increasing capillary density.
Apoptosis:
Thymosin beta-4 inhibits apoptosis by inhibiting the transforming growth factor pathway. It also prevents nucleus pulposus (spinal disk providing shock absorption during movement) cell apoptosis and slows down cellular aging.
Inflammation:
In mouse models Tβ4 significantly dropped the number of inflammatory cells in the brains of the treated animals. It also prevented the production of proinflammatory cytokines and effectively blocked the increase of ethanol-induced inflammatory factors.
Heart Health:
Clinical data showed that thymosin beta-4 has a positive effect on both acute phase (immediately following the injury) where it preserves the ischemic myocardium, as well as in the chronic phase, in which it activates the growth of vascular cells.
After observing Tβ4’s benefits in animal models, it’s not surprising TB-500 gained so much popularity recently, since it acts as Tβ4’s synthetic analogue. Numerous clinical studies (in animal models) showed TB-500 as a potent way to improve blood vessel growth and fluid flow, accelerate wound healing, reduce oxidative stress and bind protein.
Of course, more research is needed to determine the full effects of this peptide, its safety and effectiveness in human test subjects.
Reference:
Xing Y, Ye Y, Zuo H, Li Y. Progress on the Function and Application of Thymosin β4. Front Endocrinol (Lausanne). 2021 Dec 21;12:767785. doi: 10.3389/fendo.2021.767785. PMID: 34992578; PMCID: PMC8724243.
-
Tesamorelin $75.00 – $130.00
Tesamorelin is a 44 amino acid long, synthetic growth hormone releasing hormone (GHRH) analogue. It was primarily developed and used to treat visceral fat buildup in HIV positive patients suffering from lipodystrophy (a condition characterized by abnormal fat distribution).
Tesamorelin peptide activates GHRH receptors in the pituitary gland, resulting in growth hormone synthesis and release. This GH release further stimulates the production of Ilike growth factor-1 (IGF-1), which is naturally low in obese and diabetic patients.
The good thing about tesamorelin is that it was approved in the US back in 2010 for the treatment of abdominal fat in HIV positive patients as a part of the antiviral therapy-related lipodystrophy. It has also been evaluated as a potential therapy of insulin resistance, nonalcoholic fatty liver and, of course, obesity. These clinical studies are still ongoing and we’ll need more information to confirm its effectiveness.
The usual tesamorelin dosage for patients is 2mg given in the form of a subcutaneous injection, once a week. As for the side effects, patients did not report that many, but from the ones we have documented, most common are:
- Application site irritation
- Itching
- Peripheral edema
- Mild nausea
- Redness
More importantly, tirzepatide therapy was not associated with hepatotoxicity and is very unlikely to cause any clinically apparent liver injuries.
Reference:
-
Tesamorelin, Ipamorelin 10mg $110.00
Tesamorelin and Ipamorelin are two peptides combined in a blend that seems to be sharing the potential to stimulate the growth hormone axis, although through different mechanisms. This combination might activate the pituitary gland, which further results in the release of endogenous growth hormone. The blend seems to be showing positive effects on mammals and primates in terms of sleep, lipid profile, mean mass, muscle tissues, cognition, and metabolic function.
Chemical Structure
Molecular Formula
- Tesamorelin: C221H366N72O67S
- Ipamorelin: C38H49N9O5
Molecular Weight
- Tesamorelin: 5136 g/mol
- Ipamorelin: 711.9 g/mol
Sequence
- Tesamorelin: Unk-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
- Ipamorelin: H-Aib-His-D-2Nal-D-Phe-Lys-NH2
Tesamorelin and Ipamorelin Blend – GH Deficiency
Tesamorelin is an analog of the growth hormone-releasing hormone. It binds GHRG receptors on somatotrophs in the pituitary gland. Considering that it promotes the release of GH, Tesamorelin could boost lipolysis, reduce visceral adipose tissue, and potentially improve glucose metabolism.
Ipamorelin is a GHSR antagonist as well. However, it appears to be activating GHSR in the peripheral tissues and hypothalamus, potentially causing the release of GH. Researchers suggest that since GHSR stimulates the increase of GH secretion, it can promote lipolysis, protein synthesis, and IGF-1 production.
When combined, these two compounds target different components of the GH axis. This dual action seems to positively affect and amplify the overall GH, like insulin sensitivity, lipid profile, body composition, and overall metabolic function in a laboratory setting.
Tesamorelin and Ipamorelin Blend and Type 2 Diabetes
Research has shown that both Tesamorelin and Ipamorelin may help manage blood sugar levels and address metabolic issues in people with Type 2 Diabetes (T2DM). Tesamorelin works by boosting the body’s own production of growth hormone, which experts believe improves how the body responds to insulin and uses glucose. On the other hand, studies on Ipamorelin suggest it may positively affect insulin sensitivity and glucose regulation. When used together, these peptides could offer combined benefits, potentially leading to lower HbA1c levels, better insulin sensitivity, and reduced abdominal fat with T2DM.
Other benefits
- In animal models, this blend seems to have a positive effect on the following:
- Cognitive improvement – may improve memory and learning abilities.
- Muscle density – might enhance muscle density and size.
- Appetite and digestion – according to one research, animals that were given this blend managed to decrease their weight by 15%.
References:
Adrian S, Scherzinger A, Sanyal A, Lake JE, Falutz J, Dubé MP, Stanley T, Grinspoon S, Mamputu JC, Marsolais C, Brown TT, Erlandson KM. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging. 2019;8(3):154-159. doi: 10.14283/jfa.2018.45. PMID: 31237318; PMCID: PMC6766405.
Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017 Jun 15;12(6):e0179538. doi: 10.1371/journal.pone.0179538. PMID: 28617838; PMCID: PMC5472315.
https://pubchem.ncbi.nlm.nih.gov/compound/Tesamorelin#section=Deprecated-CAS
Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011 Jan;96(1):150-8. doi: 10.1210/jc.2010-1587. Epub 2010 Oct 13. PMID: 20943777; PMCID: PMC3038486.
https://www.sciencedirect.com/science/article/abs/pii/S1096637401902394?via%3Dihub
